KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Current Assets (2016 - 2025)

Historic Current Assets for TherapeuticsMD (TXMD) over the last 16 years, with Q3 2025 value amounting to $14.5 million.

  • TherapeuticsMD's Current Assets rose 1932.7% to $14.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.5 million, marking a year-over-year increase of 1932.7%. This contributed to the annual value of $12.3 million for FY2024, which is 392.51% up from last year.
  • Latest data reveals that TherapeuticsMD reported Current Assets of $14.5 million as of Q3 2025, which was up 1932.7% from $13.5 million recorded in Q2 2025.
  • In the past 5 years, TherapeuticsMD's Current Assets ranged from a high of $187.0 million in Q1 2021 and a low of $11.5 million during Q1 2024
  • Moreover, its 5-year median value for Current Assets was $19.6 million (2023), whereas its average is $58.6 million.
  • Per our database at Business Quant, TherapeuticsMD's Current Assets skyrocketed by 3065.45% in 2021 and then plummeted by 8010.91% in 2023.
  • TherapeuticsMD's Current Assets (Quarter) stood at $119.5 million in 2021, then tumbled by 53.67% to $55.4 million in 2022, then crashed by 78.69% to $11.8 million in 2023, then grew by 3.93% to $12.3 million in 2024, then rose by 18.3% to $14.5 million in 2025.
  • Its Current Assets stands at $14.5 million for Q3 2025, versus $13.5 million for Q2 2025 and $12.5 million for Q1 2025.